Polyethylene Glycol–Derivatized Cysteine-Substitution Variants of Recombinant Staphylokinase for Single-Bolus Treatment of Acute Myocardial Infarction
- 10 October 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 102 (15) , 1766-1772
- https://doi.org/10.1161/01.cir.102.15.1766
Abstract
Background—Thrombolytic therapy of acute myocardial infarction (AMI) is evolving toward bolus administration. Derivatization of proteins with polyethylene glycol (PEG) may reduce their clearance. M...Keywords
This publication has 10 references indexed in Scilit:
- Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopesBlood, 2000
- Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinaseBlood, 2000
- Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trialThe Lancet, 1999
- Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agentNature Medicine, 1998
- A Comparison of Reteplase with Alteplase for Acute Myocardial InfarctionNew England Journal of Medicine, 1997
- Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarctionAmerican Heart Journal, 1997
- Biomedical and biotechnological applications of PEG- and PM-modified proteinsTrends in Biotechnology, 1995
- A hamster pulmonary embolism model for the evaluation of the thrombolytic and pharmacokinetic properties of thrombolytic agentsFibrinolysis, 1990
- PharmacokineticsPublished by Taylor & Francis ,1982
- Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase.Journal of Biological Chemistry, 1977